Versant Ventures

Granite Bio is a biotechnology company that specializes in the development of novel monoclonal antibodies aimed at treating inflammatory, autoimmune, and fibrotic disorders. The company's primary focus is on creating therapeutic antibodies that deplete pathogenic cells and selectively target key biological pathways associated with these diseases. By advancing innovative antibody treatments, Granite Bio aims to contribute significantly to the fields of biotechnology and pharmaceuticals, addressing critical needs in the life sciences sector.

Helicore Biopharma is a biopharmaceutical company dedicated to developing innovative treatments for obesity and related metabolic disorders. Its portfolio includes novel therapeutics based on glucose-dependent insulinotropic peptide (GIP) antagonism and monoclonal antibodies that bind circulating GIP ligands, forming a modular platform for anti-obesity medicines. The company aims to help patients with obesity and related conditions achieve significant weight loss.

Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, established in 2014. The company is dedicated to researching and developing innovative therapies for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its focus is on creating disease-modifying treatments that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increase the risk of lung infections. By targeting these mechanisms, Enterprise Therapeutics aims to improve the quality of life for patients suffering from these debilitating conditions.

Tentarix Biotherapeutics is a company focused on developing innovative protein therapeutics that address critical limitations in the treatment of cancer, autoimmune diseases, and other conditions. Utilizing a protein engineering platform, Tentarix specializes in creating multispecific binding molecules that combine unique bioactivities derived from fully human antibody variable domains. By leveraging synthetic biology, the company aims to provide clinicians with new therapeutic options that offer enhanced specificity and activity, thereby improving patient outcomes in various disease contexts.

Belharra Therapeutics is a privately held drug discovery company based in the San Francisco Bay Area, with its primary laboratory and offices located in San Diego. The company is focused on developing transformative small molecule drugs to address serious diseases using its innovative photoaffinity-based chemoproteomics platform. This cutting-edge technology allows Belharra scientists to identify small molecule drug candidates that can target any binding site on any protein, regardless of its conformational state or cell type. By integrating advanced biology, medicinal chemistry, and bioinformatics with drug discovery and chemoproteomics screening, Belharra aims to deliver first-in-class medicines that have the potential to significantly improve patient outcomes.

Launchpad Therapeutics is a precision oncology company focused on developing innovative antibody-based treatments for cancer. The company specializes in creating mutant-selective antibodies designed to target specific mutations found in cancer cells. By leveraging artificial intelligence-driven programs, Launchpad Therapeutics aims to deliver novel monoclonal antibodies that offer new avenues for cancer treatment. These efforts are directed towards providing medical professionals with alternative and effective therapeutic options for patients.

iECURE is a biotechnology company dedicated to developing innovative gene editing therapies aimed at treating rare and life-threatening liver disorders, particularly in children. Its approach employs mutation-agnostic in vivo gene insertion techniques, which allow for targeted interventions in diseases characterized by metabolic "loss of function" disorders. By focusing on conditions with high unmet medical needs, iECURE aims to offer potential cures for devastating illnesses that currently lack effective treatment options. The company's commitment to advancing gene editing technology positions it as a key player in the field of genetic medicine.

Nested Therapeutics is a stealth biotechnology company based in Cambridge, Massachusetts, founded in 2021. The company specializes in the development of precision oncology therapies aimed at targeting specific cancer genes. By identifying new driver mutations, Nested Therapeutics employs a platform that integrates insights from genomics, computational chemistry, proteomics, and artificial intelligence to discover novel small-molecule drugs. This innovative approach enables healthcare professionals to administer more effective precision medications, ultimately improving treatment outcomes for cancer patients.

Tentarix Biotherapeutics is a company focused on developing innovative protein therapeutics that address critical limitations in the treatment of cancer, autoimmune diseases, and other conditions. Utilizing a protein engineering platform, Tentarix specializes in creating multispecific binding molecules that combine unique bioactivities derived from fully human antibody variable domains. By leveraging synthetic biology, the company aims to provide clinicians with new therapeutic options that offer enhanced specificity and activity, thereby improving patient outcomes in various disease contexts.

iECURE is a biotechnology company dedicated to developing innovative gene editing therapies aimed at treating rare and life-threatening liver disorders, particularly in children. Its approach employs mutation-agnostic in vivo gene insertion techniques, which allow for targeted interventions in diseases characterized by metabolic "loss of function" disorders. By focusing on conditions with high unmet medical needs, iECURE aims to offer potential cures for devastating illnesses that currently lack effective treatment options. The company's commitment to advancing gene editing technology positions it as a key player in the field of genetic medicine.

Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, established in 2014. The company is dedicated to researching and developing innovative therapies for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its focus is on creating disease-modifying treatments that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increase the risk of lung infections. By targeting these mechanisms, Enterprise Therapeutics aims to improve the quality of life for patients suffering from these debilitating conditions.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

PIQUR Therapeutics AG is a clinical-stage pharmaceutical company based in Basel, Switzerland, founded in 2011. The company specializes in the discovery and development of innovative anti-cancer drugs, focusing on lipid kinase (PI3K) and mTOR inhibition, which are recognized as effective drug targets in oncology. PIQUR's pipeline includes promising compounds, with its lead drug, bimiralisib, designed to dual inhibit the PI3K/mTOR pathway. By developing targeted therapies for oncology and dermatology, PIQUR Therapeutics aims to improve the lives of cancer patients and address genetic diseases, ultimately enhancing their recovery and overall quality of life. The company holds a secured patent scope that protects many of its chemical compounds, reinforcing its commitment to advancing cancer treatment.

Ceterix Orthopaedics, Inc. is a medical technology company that specializes in developing innovative surgical tools for arthroscopic procedures. Founded in October 2010 and based in Fremont, California, Ceterix offers the NovoStitch® Plus Meniscal Repair System, designed to address complex meniscal tears, including horizontal, radial, and root tears. The company also provides the Novocut Suture Manager, a device that facilitates efficient suture management. Ceterix's technology enables orthopedic surgeons to create intricate suture patterns in tight joint compartments while safeguarding surrounding structures, such as nerves and cartilage. This advancement allows for improved outcomes in arthroscopic procedures across various joints, including the knees, hips, and shoulders. Ceterix was previously known as SuturePro Technologies, Inc. before rebranding in April 2011 and is currently a subsidiary of Smith & Nephew plc.

PIQUR Therapeutics AG is a clinical-stage pharmaceutical company based in Basel, Switzerland, founded in 2011. The company specializes in the discovery and development of innovative anti-cancer drugs, focusing on lipid kinase (PI3K) and mTOR inhibition, which are recognized as effective drug targets in oncology. PIQUR's pipeline includes promising compounds, with its lead drug, bimiralisib, designed to dual inhibit the PI3K/mTOR pathway. By developing targeted therapies for oncology and dermatology, PIQUR Therapeutics aims to improve the lives of cancer patients and address genetic diseases, ultimately enhancing their recovery and overall quality of life. The company holds a secured patent scope that protects many of its chemical compounds, reinforcing its commitment to advancing cancer treatment.

CardiAQ Valve Technologies is a privately held company dedicated to advancing heart valve replacement procedures. Its primary focus is on developing innovative techniques for transcatheter mitral valve implantation (TMVI), aiming to enable physicians to implant mitral valves within a beating heart without the need for open-heart surgery.

Inogen is a medical technology company specializing in oxygen therapy solutions for patients with chronic respiratory conditions. The company designs and manufactures portable oxygen concentrators, with its flagship product being the Inogen One system, which offers a lightweight and convenient alternative to traditional stationary oxygen concentrators and oxygen tanks. Inogen sells its products to home medical equipment providers and directly rents devices to patients, primarily generating its revenue in the United States. Additionally, the company distributes its products internationally through partnerships with large gas companies and home oxygen providers. Inogen's mission is to enhance the freedom and independence of oxygen therapy users by providing innovative and user-friendly products and services.

Acclarent, Inc. is a medical device company focused on developing innovative technologies for ear, nose, and throat (ENT) patients. The company specializes in balloon sinuplasty devices, which are minimally invasive tools designed to assist physicians in treating chronic sinusitis. These devices enable doctors to navigate sinus anatomy effectively, facilitating the opening of blocked sinus ostia and passageways to promote proper sinus drainage. Acclarent's Balloon Sinuplasty technology and associated Relieva product portfolio provide alternatives to traditional endoscopic surgical methods. The company's devices received FDA clearance and were commercially launched in the United States in 2005, marking a significant advancement in the treatment options available for patients with sinus-related conditions.

CodeRyte is a leading provider of computer-assisted coding and clinical data extraction solutions tailored for the healthcare industry. The company offers advanced software products, including CodeAssist, which automates the coding process by integrating with user operational information systems, and CodeComplete, an outsourced coding solution. Additionally, CodeRyte's DataScout tool analyzes physician narratives to extract clinically relevant information from both free-text and structured medical records. By streamlining coding processes and improving data extraction, CodeRyte enables healthcare providers to secure appropriate reimbursements, enhance compliance, and make informed treatment and business decisions. Its solutions are utilized by many prominent physician practices, billing companies, and academic medical centers across the nation, positioning CodeRyte as a vital component of their coding and data-mining operations.

PhaseRx is a Seattle-based biopharmaceutical startup focused on developing intracellular enzyme replacement therapies for inherited liver diseases using its proprietary Hybrid mRNA Technology platform. This platform enables the synthesis of missing enzymes within cells, targeting three urea cycle disorders: ornithine transcarbamylase deficiency (OTCD), argininosuccinate lyase deficiency (ASL deficiency), and argininosuccinate synthetase deficiency (ASS1 deficiency). The company was founded by industry veterans and renowned academics, attracting top-tier venture capital investments.

Inogen is a medical technology company specializing in oxygen therapy solutions for patients with chronic respiratory conditions. The company designs and manufactures portable oxygen concentrators, with its flagship product being the Inogen One system, which offers a lightweight and convenient alternative to traditional stationary oxygen concentrators and oxygen tanks. Inogen sells its products to home medical equipment providers and directly rents devices to patients, primarily generating its revenue in the United States. Additionally, the company distributes its products internationally through partnerships with large gas companies and home oxygen providers. Inogen's mission is to enhance the freedom and independence of oxygen therapy users by providing innovative and user-friendly products and services.

Acclarent, Inc. is a medical device company focused on developing innovative technologies for ear, nose, and throat (ENT) patients. The company specializes in balloon sinuplasty devices, which are minimally invasive tools designed to assist physicians in treating chronic sinusitis. These devices enable doctors to navigate sinus anatomy effectively, facilitating the opening of blocked sinus ostia and passageways to promote proper sinus drainage. Acclarent's Balloon Sinuplasty technology and associated Relieva product portfolio provide alternatives to traditional endoscopic surgical methods. The company's devices received FDA clearance and were commercially launched in the United States in 2005, marking a significant advancement in the treatment options available for patients with sinus-related conditions.

Inogen is a medical technology company specializing in oxygen therapy solutions for patients with chronic respiratory conditions. The company designs and manufactures portable oxygen concentrators, with its flagship product being the Inogen One system, which offers a lightweight and convenient alternative to traditional stationary oxygen concentrators and oxygen tanks. Inogen sells its products to home medical equipment providers and directly rents devices to patients, primarily generating its revenue in the United States. Additionally, the company distributes its products internationally through partnerships with large gas companies and home oxygen providers. Inogen's mission is to enhance the freedom and independence of oxygen therapy users by providing innovative and user-friendly products and services.

Vantage Oncology, Inc. specializes in providing comprehensive oncology care services, focusing on radiation oncology, medical oncology, and cancer treatment. The company addresses the increasing demand for advanced radiation therapies among cancer patients, hospitals, and physicians. Vantage offers a range of services, including radiation therapy and neurosurgical interventions for various cancer types, such as breast, lung, and prostate cancers. Additionally, Vantage promotes joint venture ownership opportunities, allowing physicians and hospitals to maintain control over their practices while benefiting from the company's extensive network and expertise in radiation oncology. This model not only enhances the capabilities of individual practices but also strengthens the overall quality of cancer care provided to patients.

Vantage Oncology, Inc. specializes in providing comprehensive oncology care services, focusing on radiation oncology, medical oncology, and cancer treatment. The company addresses the increasing demand for advanced radiation therapies among cancer patients, hospitals, and physicians. Vantage offers a range of services, including radiation therapy and neurosurgical interventions for various cancer types, such as breast, lung, and prostate cancers. Additionally, Vantage promotes joint venture ownership opportunities, allowing physicians and hospitals to maintain control over their practices while benefiting from the company's extensive network and expertise in radiation oncology. This model not only enhances the capabilities of individual practices but also strengthens the overall quality of cancer care provided to patients.

Acclarent, Inc. is a medical device company focused on developing innovative technologies for ear, nose, and throat (ENT) patients. The company specializes in balloon sinuplasty devices, which are minimally invasive tools designed to assist physicians in treating chronic sinusitis. These devices enable doctors to navigate sinus anatomy effectively, facilitating the opening of blocked sinus ostia and passageways to promote proper sinus drainage. Acclarent's Balloon Sinuplasty technology and associated Relieva product portfolio provide alternatives to traditional endoscopic surgical methods. The company's devices received FDA clearance and were commercially launched in the United States in 2005, marking a significant advancement in the treatment options available for patients with sinus-related conditions.

Vantage Oncology, Inc. specializes in providing comprehensive oncology care services, focusing on radiation oncology, medical oncology, and cancer treatment. The company addresses the increasing demand for advanced radiation therapies among cancer patients, hospitals, and physicians. Vantage offers a range of services, including radiation therapy and neurosurgical interventions for various cancer types, such as breast, lung, and prostate cancers. Additionally, Vantage promotes joint venture ownership opportunities, allowing physicians and hospitals to maintain control over their practices while benefiting from the company's extensive network and expertise in radiation oncology. This model not only enhances the capabilities of individual practices but also strengthens the overall quality of cancer care provided to patients.

Vantage Oncology, Inc. specializes in providing comprehensive oncology care services, focusing on radiation oncology, medical oncology, and cancer treatment. The company addresses the increasing demand for advanced radiation therapies among cancer patients, hospitals, and physicians. Vantage offers a range of services, including radiation therapy and neurosurgical interventions for various cancer types, such as breast, lung, and prostate cancers. Additionally, Vantage promotes joint venture ownership opportunities, allowing physicians and hospitals to maintain control over their practices while benefiting from the company's extensive network and expertise in radiation oncology. This model not only enhances the capabilities of individual practices but also strengthens the overall quality of cancer care provided to patients.

Inogen is a medical technology company specializing in oxygen therapy solutions for patients with chronic respiratory conditions. The company designs and manufactures portable oxygen concentrators, with its flagship product being the Inogen One system, which offers a lightweight and convenient alternative to traditional stationary oxygen concentrators and oxygen tanks. Inogen sells its products to home medical equipment providers and directly rents devices to patients, primarily generating its revenue in the United States. Additionally, the company distributes its products internationally through partnerships with large gas companies and home oxygen providers. Inogen's mission is to enhance the freedom and independence of oxygen therapy users by providing innovative and user-friendly products and services.

NeoGuide Systems Inc. is a developer of robotic endoscopic technology specifically designed for natural orifice transluminal endoscopic surgery (NOTES). Founded in 2000 and based in San Jose, California, the company focuses on creating advanced solutions for medical procedures, particularly in colonoscopy applications. Its innovative technology aims to enhance the visualization and delivery of therapies within the body, thereby improving access to abdominal and thoracic cavities. NeoGuide is positioned at the forefront of a transformative approach in minimally invasive surgery, contributing to the evolution of medical practices in the field.

Vantage Oncology, Inc. specializes in providing comprehensive oncology care services, focusing on radiation oncology, medical oncology, and cancer treatment. The company addresses the increasing demand for advanced radiation therapies among cancer patients, hospitals, and physicians. Vantage offers a range of services, including radiation therapy and neurosurgical interventions for various cancer types, such as breast, lung, and prostate cancers. Additionally, Vantage promotes joint venture ownership opportunities, allowing physicians and hospitals to maintain control over their practices while benefiting from the company's extensive network and expertise in radiation oncology. This model not only enhances the capabilities of individual practices but also strengthens the overall quality of cancer care provided to patients.

Syrrx Inc is a biotechnology company that specializes in the development of novel small molecule drugs aimed at treating cancer, metabolic diseases, and inflammation. By leveraging its expertise in high-throughput structural biology, Syrrx is able to determine the three-dimensional structures of drug targets that have been validated in human clinical trials. This foundational work supports their iterative, structure-based drug design programs, which efficiently generate potential drug candidates. The company has established partnerships for the development and commercialization of its designed human dipeptidyl peptidase IV (DPP IV) inhibitors for the treatment of type 2 diabetes and other significant diseases. Additionally, Syrrx has a strategic alliance focused on discovering and early developing inhibitors that target human histone deacetylases (HDACs) and 11β-hydroxysteroid dehydrogenase type 1 (HSD1), further expanding its therapeutic portfolio.